How does COVID-19 immunity hold up against Deltacron?

Embargoed until: Publicly released: 2022-05-19 12:30

International

Photo by Viktor Forgacs on Unsplash

Deltacron, a COVID-19 variant that is a hybrid of Delta and Omicron, is significantly better at evading antibodies generated by vaccines and COVID-19 infection, according to international research. The team tested Omicron BA1, BA2, BA3 and Deltacron against serum from recently double and triple vaccinated healthcare workers alongside vaccinated and unvaccinated patients hospitalised with COVID-19 during Delta and Omicron waves. They say while neutralising antibodies held up well against BA3, Deltacron was similarly good at evading immunity compared to BA1 and BA2. A third dose causes a major increase in antibody levels against Deltacron, they say.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: Ohio State University, USA

Funder: Supported by a fund provided by a private donor to Ohio State University (to Dr. Liu); by an award (U54CA260582, to Drs. Liu, Lozanski, Gumina, Saif, and Oltz) from the National Cancer Institute of the National Institutes of Health (NIH); a grant (R01 AI150473, to Dr. Liu) from the NIH; a Glenn Barber Fellowship (to Mr. Evans) from the Ohio State University College of Veterinary Medicine; grants (to Dr. Gumina) from the Robert J. Anthony Fund for Cardiovascular Research and the JB Cardiovascular Research Fund; by a grant (R01 HD095881, to Dr. Saif) from the NIH; and by grants (UL1TR002733 and KL2TR002734, to Dr. Bednash) from the National Center for Advancing Translational Sciences.

Media Contact/s

Contact details are only visible to registered journalists.